Welcome to our dedicated page for Apimeds Pharmaceuticals US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apimeds Pharmaceuticals US, Inc. filings document a Delaware clinical-stage biopharmaceutical issuer with common stock registered on NYSE American under APUS and emerging growth company status. Recent 8-K and 12b-25 records cover material definitive agreements, governance and executive changes, shareholder written-consent and voting matters, preferred stock and convertible-note conversion disclosures, and capital-structure matters.
The filing record also includes notices tied to delayed Form 10-K reporting and NYSE American continued-listing compliance, along with disclosures related to settlement agreements and merger-related governance matters. Periodic and event filings frame Apimeds' operating and financial results, risk factors, and clinical or regulatory disclosures for the Apitox program.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s grant of stock options. The filing shows 3,000 stock options acquired on 10/15/2025 at an exercise price of $1.92 per share, expiring on 10/15/2035. Following the transaction, the reporting person beneficially owns 3,000 derivative securities, held directly.
The options vest in quarterly installments beginning October 1, 2025 and become fully vested after three years, with full vesting upon a Change in Control as defined in the plan. The options are not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. The company’s Chief Executive Officer and Director received a stock option to purchase 215,000 shares at an exercise price of $1.92 on 10/15/2025. The option vests in quarterly installments beginning October 1, 2025 and is fully vested after three years, with full vesting upon a Change in Control. It is not exercisable until stockholders approve an amendment to the incentive plan to increase available shares. The option expires on 10/15/2035.
Apimeds Pharmaceuticals US, Inc. reported a corporate governance change. On October 15, 2025, the board amended the company’s bylaws to allow shareholder action by written consent, enabling stockholders to take certain actions without a meeting when the required consents are obtained.
The full text of the amendment is provided as Exhibit 3.1 to the report.
Apimeds Pharmaceuticals US, Inc. reported interim results showing a May 12, 2025 IPO that sold 3,375,000 shares at $4.00 per share, generating net proceeds of approximately $11.9 million after underwriting discounts, offering expenses and the value of Advisor/Placement Agent warrants. Cash balances plus IPO proceeds are stated to be sufficient to fund operations for at least twelve months from the condensed financial statements issuance date. Shares outstanding increased to 12,575,983 at June 30, 2025 from 7,903,850 at December 31, 2024, reflecting the IPO and conversions of convertible notes. The company recognized stock-based compensation including $1.7 million in fully vested stock grants and stock option expense of $192,053. Advisor and placement agent warrants were recorded as liabilities or reductions to additional paid-in capital with remeasurement activity of $9,518. Convertible notes and promissory notes were amended, converted, or extended, and certain related-party financing activity is disclosed.